Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
CardiovascularINJECTIONGeneric

AMPHOTEC

AMPHOTERICIN B

Standard Dose
50MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview AMPHOTEC is listed in Drugs@FDA under application 050729 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient AMPHOTERICIN B Form and strength INJECTABLE, LIPID COMPLEX;INJECTION - 50MG/VIAL Sponsor ALKOPHARMA USA Submission history Latest submission status date: 1997-08-27 00:00:00.

Structured Monograph

Clinical summary

Approval overview AMPHOTEC is listed in Drugs@FDA under application 050729 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient AMPHOTERICIN B Form and strength INJECTABLE, LIPID COMPLEX;INJECTION - 50MG/VIAL Sponsor ALKOPHARMA USA Submission history Latest submission status date: 1997-08-27 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.